FDA Inspection 1010068 — Fresenius Kabi Oncology Limited
The FDA completed an inspection of Fresenius Kabi Oncology Limited on April 14, 2017 in Baddi. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- April 14, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Baddi (India)